Skip to search formSkip to main contentSkip to account menu

alisertib

Known as: Benzoic Acid, 4-((9-Chloro-7-(2-Fluoro-6-Methoxyphenyl)-5H-Pyrimido(5,4-d)(2)Benzazepin-2-yl)Amino)-2-Methoxy- 
A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with… 
National Institutes of Health

Related topics

Related topics

3 relations
Aurora Kinase ANCIt Antineoplastic Agent Terminology

Broader (1)

MLN 8237

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)
Purpose: Aurora A kinase (AAK) plays an integral role in mitotic entry, DNA damage checkpoint recovery, and centrosome and… 
Highly Cited
2018
Highly Cited
2018
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Purpose: In phase I testing, alisertib tablets with irinotecan and temozolomide showed significant antitumor activity in patients… 
Review
2018
Review
2018
Molecularly Targeted Therapy for Neuroblastoma
Neuroblastoma is the most common extra-cranial solid tumor encountered in childhood and accounts for 15% of pediatric cancer… 
Highly Cited
2015
Highly Cited
2015
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
PURPOSE Aurora A kinase (AAK) is upregulated in highly proliferative lymphomas, suggesting its potential as a therapeutic target… 
Highly Cited
2015
Highly Cited
2015
Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.
BACKGROUND Aurora Kinase A (AURKA) encodes a protein that regulates the formation and stability of the mitotic spindle and is… 
Highly Cited
2015
Highly Cited
2015
The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells
Alisertib (ALS) is an investigational potent Aurora A kinase inhibitor currently undergoing clinical trials for the treatment of… 
Review
2014
Review
2014
Recent advances in diagnosis and treatment of gliomas using chlorotoxin-based bioconjugates.
Malignant gliomas, especially glioblastoma multiforme, are the most widely distributed and deadliest brain tumors because of… 
Highly Cited
2012
Highly Cited
2012
Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL
Highly Cited
2012
Highly Cited
2012
Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
Purpose: This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational oral… 
Highly Cited
2012
Highly Cited
2012
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO‐dependent mechanism
Novel therapies are urgently needed to improve clinical outcomes for patients with acute myeloid leukemia (AML). The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)